Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents
The American Journal of Cardiology 96(3): 395-398
Article 2005 English
Authors
KT
Keiichi Tsuchida
AO
Andrew T.L. Ong
JA
Jiro Aoki
Abstract
1 min read
The aim of this study was to evaluate the outcome after paclitaxel-eluting stent implantation in 40 patients with 52 saphenous vein graft lesions. By Kaplan-Meier estimates, the probability of major adverse cardiac event-free survival for 1 year was 92.5%. A paclitaxel-eluting stent for saphenous vein graft disease appears to be feasible and safe, with a low rate of reintervention at 1 year, but late follow-up is needed to confirm these observations.
Masanori Taniwaki, Lorenz Räber, Michael Magro, Bindu Kalesan, Yoshinobu Onuma, Giulio Stefanini, Ron T. van Domburg, Aris Moschovitis, Bernhard Meier, Peter Jüni, Patrick W. Serruys, Stephan Windecker
Keiichi Tsuchida, Joost Daemen, Shuzou Tanimoto, Héctor M. García‐García, Neville Kukreja, Sophia Vaina, Andrew T.L. Ong, Georgios Sianos, Peter P.T. de Jaegere, Ron T. van Domburg, Patrick W. Serruys
Cihan Şimşek, Michael Magro, Eric Boersma, Yoshinobu Onuma, Sjoerd T. Nauta, Marcia P. Gaspersz, Willem J. van der Giessen, Ron T. van Domburg, Patrick W. Serruys
Angela Hoye, Pedro A. Lemos, Chourmouzios A Arampatzis, Francesco Saia, Kengo Tanabe, Muzaffer Degertekin, Sjoerd H. Hofma, Eugène McFadden, Georgios Sianos, Pieter C Smits, Willem J. van der Giessen, Pim de Feyter, Ron T. van Domburg, Patrick W. Serruys
Marie-Claude Morice, Antonio Colombo, Bernhard Meier, Patrick W. Serruys, Corrado Tamburino, Giulio Guagliumi, Eduardo Sousa, Hans-Peter Stoll, for the REALITY Trial Investigators
Discussion(0)
No comments yet. Be the first to comment.